DK171968B1 - 5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse - Google Patents

5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse Download PDF

Info

Publication number
DK171968B1
DK171968B1 DK368486A DK368486A DK171968B1 DK 171968 B1 DK171968 B1 DK 171968B1 DK 368486 A DK368486 A DK 368486A DK 368486 A DK368486 A DK 368486A DK 171968 B1 DK171968 B1 DK 171968B1
Authority
DK
Denmark
Prior art keywords
dhea
compound according
mice
tpa
compounds
Prior art date
Application number
DK368486A
Other languages
Danish (da)
English (en)
Other versions
DK368486D0 (da
DK368486A (da
Inventor
Arthur G Schwartz
Marvin Louis Lewbart
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of DK368486D0 publication Critical patent/DK368486D0/da
Publication of DK368486A publication Critical patent/DK368486A/da
Application granted granted Critical
Publication of DK171968B1 publication Critical patent/DK171968B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK368486A 1985-08-02 1986-08-01 5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse DK171968B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76258485A 1985-08-02 1985-08-02
US76258485 1985-08-02

Publications (3)

Publication Number Publication Date
DK368486D0 DK368486D0 (da) 1986-08-01
DK368486A DK368486A (da) 1987-02-03
DK171968B1 true DK171968B1 (da) 1997-09-01

Family

ID=25065487

Family Applications (1)

Application Number Title Priority Date Filing Date
DK368486A DK171968B1 (da) 1985-08-02 1986-08-01 5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse

Country Status (11)

Country Link
EP (1) EP0210665B1 (ja)
JP (1) JP2512439B2 (ja)
AU (1) AU598201B2 (ja)
CA (1) CA1314871C (ja)
DE (1) DE3666437D1 (ja)
DK (1) DK171968B1 (ja)
ES (1) ES2000613A6 (ja)
GR (1) GR862043B (ja)
IE (1) IE58540B1 (ja)
IL (1) IL79583A (ja)
PT (1) PT83138B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60027B1 (en) * 1986-05-21 1994-05-18 Research Corp Steroids useful as anti-cancer and anti-obesity agents
US5175154A (en) * 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
US5028631A (en) * 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
JP3029907B2 (ja) * 1991-12-20 2000-04-10 理化学研究所 抗肥満剤
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
EP0907351B2 (de) * 1996-03-29 2012-04-18 Keyvest GmbH Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
CN103409144B (zh) * 2013-08-16 2014-11-26 东北大学 含甾体基元的环状碳酸酯类活泼液晶单体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS598074B2 (ja) * 1979-01-23 1984-02-22 沖電気工業株式会社 発光素子アレイ装置
JPS59155140U (ja) * 1983-04-06 1984-10-18 沖電気工業株式会社 光プリントヘツドの組立構造
JPS6069096A (ja) * 1983-08-02 1985-04-19 リサ−チ・コ−ポレイシヨン 新規ステロイド
JPS6162016A (ja) * 1984-09-03 1986-03-29 Nhk Spring Co Ltd Ｌｅｄプリンタヘツド

Also Published As

Publication number Publication date
CA1314871C (en) 1993-03-23
GR862043B (en) 1986-12-24
IE862062L (en) 1987-02-02
PT83138B (pt) 1989-03-30
AU598201B2 (en) 1990-06-21
ES2000613A6 (es) 1988-03-01
JP2512439B2 (ja) 1996-07-03
AU6079786A (en) 1987-02-05
JPS6248693A (ja) 1987-03-03
EP0210665A1 (en) 1987-02-04
PT83138A (en) 1986-09-01
DE3666437D1 (en) 1989-11-23
IE58540B1 (en) 1993-10-06
DK368486D0 (da) 1986-08-01
EP0210665B1 (en) 1989-10-18
IL79583A (en) 1990-11-29
DK368486A (da) 1987-02-03
IL79583A0 (en) 1986-11-30

Similar Documents

Publication Publication Date Title
EP0133995B1 (en) Steroids and therapeutic compositions containing same
KR950003614B1 (ko) 치환된 안드로스타-1,4-디엔-3,17-디온의 제조방법
EP1169336B1 (en) Ent-steroids as selectively active estrogens
US5744462A (en) Steroids useful as anti-cancer and anti-obesity agents
DK171968B1 (da) 5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse
US5157031A (en) Method for prophylaxis of obesity
JP2000256390A (ja) 性ステロイド活性を抑制するために用いるエストロゲン核誘導体の医薬組成物
JPS6119640B2 (ja)
US7419972B2 (en) 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US4840943A (en) Androst-4-ene-3,17-diones and process for their preparation
US7435757B2 (en) 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US20090023695A1 (en) METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE
DK173168B1 (da) 5alfa-androsten-17-oner og 5alfa-androstan-17-oner, der er virksomme mod kræft og obesitet, samt terapeutisk middel der ind
JPS635097A (ja) アンドロスト−４−エン−３，１７−ジオンのメチレン誘導体およびその製造方法
AU3351593A (en) Difluoromethylenandrostenone derivatives and process for their preparation
IE73240B1 (en) Steroids and therapeutic compositions containing same
EP0620823A1 (en) 6,7$g(a)-DIFLUOROMETHYLENANDROSTA-1,4-DIEN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
GB2284605A (en) 6-or 7-substituted 4-aminoandrostadienone derivatives

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK